Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Key facts
- Who runs it
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Where
- Albuquerque, Anderson, Anniston, Atlanta, Beachwood, Charleston, Charlotte, Cincinnati, Clarkston, Colorado Springs, Cullman, Dallas, Farmington Hills, Fort Myers, Gulfport, Hendersonville, Huntington Park, Inverness, Jupiter, La Mesa, Lakewood, Layton, Lenexa, Little Rock, Louisville, Medford, Meridian, Miami, Miami Lakes, Monroe, Montclair, New Orleans, New York, Norfolk, North Miami, Oceanside, Omaha, Peoria, Prairieville, Prosper, Richmond, Rochester Hills, San Antonio, San Diego, Sioux City, Spartanburg, Springfield, St Louis, Stephenville, Tempe, Tucson, Tulsa, Valparaiso, and West Jordan, United StatesSee the 56 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 5,071 people enrolled
- Started
- 20 Sept 2024
- Ended
- 9 Oct 2025
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CD388 Injection
- Placebo
- Record updated
- 18 June 2026
Who can take part
- Age
- 18 years to 63 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Willing and able to provide written informed consent and comply with scheduled visits, laboratory tests, and other study procedures
- Males and females 18 to less than 64 years of age
- In the Investigator's clinical judgment, is in stable health at the time of screening and randomization. Participants may not have underlying hematologic, oncologic, renal, autoimmune, and/or cardiopulmonary illnesses or be considered at risk of developing complications from influenza infection per the CDC guidelines (chronic obstructive pulmonary disease [COPD], asthma, immune compromised current cancer [except non-melanomatous skin cancer], or diabetes). Subjects will be included on the basis of medical history and vital signs taken between signing of the informed consent and randomization
- Body mass index (BMI; calculated as weight in kilograms [kg] divided by height in meters [m] squared) of 18.0 kg/m\^2 to 35.0 kg/m\^2 (inclusive)
- Women of childbearing potential (WOCBP) must:; Have a negative pregnancy test (beta-human chorionic gonadotropin [β-hCG]) at screening, AND; Be practicing a highly effective, preferably user-independent method of contraception (failure rate of less than 1 percent per year when used consistently and correctly) from ≥2 weeks prior to randomization and agrees to remain on a highly effective method from Day 1 until 32 weeks after study drug administration, the end of relevant systemic exposure. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the day of administration of study drug; A woman is considered of childbearing potential (i.e., fertile) following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient
- Female participants must agree not to donate or freeze eggs (ova, oocytes) for future use for the purposes of assisted reproduction from Day 1 until 32 weeks after study drug administration
- Male participants must wear a condom when engaging in any activity that allows for passage of ejaculate to another person from Day 1 until 32 weeks after study drug administration. Male participants should also be advised of the benefit for a female partner to additionally use a highly effective method of contraception, as condoms could break or leak; Note: Contraceptive (birth control) use by participants should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
- Male participants must agree not to donate sperm from Day 1 until 32 weeks after study drug administration
- Participant agrees not to donate blood from Day 1 until 32 weeks after study drug administration
- Must be able to read, understand, and complete questionnaires in the electronic diary (eDiary), work with smartphones/tablets/computers, and be willing and able to adhere to the prohibitions and restrictions specified in this protocol. If an appropriate language version is not available for the eDiary assessments, the participant should not be enrolled
- Must be willing to provide verifiable identification, has means to be contacted, and is able to contact the Investigator/study site and communicate reliably during participation in the study
Who cannot take part
- Have been diagnosed with influenza (i.e., with medical history [including verbal] of influenza) within the past 6 months prior to randomization
- Has received the current seasonal influenza vaccine prior to screening or is planning to receive the seasonal vaccine during trial participation
- Has an acute illness (including acute respiratory illnesses) or body temperature ≥38.0ºC (≥100.4 degrees Fahrenheit [ºF]) within 7 days prior to study drug administration (Note: Enrollment at a later date, subsequent to resolution [within the screening period] is permitted)
- Has had close contact (including household contacts) with someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) as defined by the US CDC or has had a positive SARS-CoV-2 test within 10 days prior to screening. Please note SARS-CoV-2 testing is NOT required during screening
- Had major surgery (e.g., major cardiopulmonary or abdominal operations) per Investigator judgment within 4 weeks prior to randomization, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study
- Prior receipt within the past 30 days or 5 half-lives (whichever is longer) or anticipated receipt of any drug, vaccine, or other biologic agent (e.g., monoclonal antibodies) administered for the prevention or treatment of influenza
- Prior receipt of any experimental drug, vaccine, or biologic agent within the past 90 days or 5 half-lives (whichever is longer)
- Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibodies (including crystallizable fragment [Fc] domains), or any of the components of CD388 or placebo
- Has a serious and/or clinically unstable condition such as psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, Alzheimer's disease, or any other condition for which, in the opinion of the Investigator, participation would not be in the participant's best interest or that could prevent, confound, or limit the protocol-specified assessments
- Any history of alcohol or drug abuse within the past 2 years or a positive urine drug screen for drugs of abuse (other than tetrahydrocannabinol [THC]) at screening or Day 1. Note: urine drug screen that is positive for a medication prescribed for treatment of ongoing condition is not exclusionary
- Contraindication to SQ injections and blood draws (e.g., bleeding disorders)
- Has had close contact (including household contacts) with someone with laboratory-confirmed influenza or with someone who has been treated with antiviral therapies for influenza within the past 7 days prior to randomization
- Screening ECG findings of prolonged QT interval corrected for heart rate using Fridericias formula (QTcF) (greater than 450 milliseconds [msec] in males or greater than 470 msec in females), prolonged PR interval (greater than 220 msec), second- or third-degree heart block, or other clinically significant dysrhythmias
- Current or planned participation in another clinical study where study intervention is being administered while participating in the current study. Note: Concurrent enrollment is allowed during the follow-up phase of the other clinical study or in case the study intervention in the other clinical study is a marketed product already approved for another indication - exception being if the other study requires study interventions that could affect the safety assessments of the present study (e.g., clinical laboratory tests)
- At the time of screening, any finding that may significantly increase the risk of participation in the study, affect the ability to participate in the study, or impair interpretation of the study data
- [Exclusion criterion #13 removed during Amendment 1.1-US; placeholder remains to retain numbering of the remaining original exclusion criteria.]
- Has donated ≥450 mL of blood product (1 unit) for any reason within 30 days of screening or plans to donate blood product during the study
- Currently pregnant or breastfeeding, intends to become pregnant or breastfeed, or has a positive pregnancy test during the screening period
- Has direct involvement in the proposed study or other studies under the direction of the Investigator, sub-investigators, or study site; is a family member of an individual with such direct involvement; or is an employee of the Sponsor
- In the opinion of the Investigator, is unlikely to adhere to the requirements of the study
Where in United States
Also in 1 other country, 1 site
- Velocity Clinical Research - AlbuquerqueAlbuquerque, United States
- Velocity Clinical Research, AndersonAnderson, United States
- Pinnacle Research Group, LLCAnniston, United States
- DelRicht ResearchAtlanta, United States
- Velocity Clinical Research, ClevelandBeachwood, United States
- DelRicht ResearchCharleston, United States
- DelRicht ResearchCharlotte, United States
- Velocity Clinical Research - SpringdaleCincinnati, United States
- Profound Research LLCClarkston, United States
- Lynn Institute of the RockiesColorado Springs, United States
- Cullman Clinical TrialsCullman, United States
- Lonestar Clinical Research, LLCDallas, United States
- Zenos Clinical ResearchDallas, United States
- Profound Research, LLCFarmington Hills, United States
- Alliance for Multispecialty Research, LLCFort Myers, United States
- DelRicht ResearchGulfport, United States
- DelRicht ResearchHendersonville, United States
- Velocity Clinical Research-Huntington ParkHuntington Park, United States
- Nature Coast Clinical ResearchInverness, United States
- Health Awareness, LLCJupiter, United States
- Velocity Clinical Research, San DiegoLa Mesa, United States
- Critical Care, Pulmonary & Sleep Associates, PLLP/CCT ResearchLakewood, United States
- Alliance for Multispecialty Research, LLCLayton, United States
- Johnson County Clin-TrialsLenexa, United States
- Baptist Health Center for Clinical ResearchLittle Rock, United States
- DelRicht ResearchLouisville, United States
- Velocity Clinical Research, MedfordMedford, United States
- Velocity Clinical Research, BoiseMeridian, United States
- Clinical Site Partners LLC, dba Flourish ResearchMiami, United States
- South Florida Research Center, Inc.Miami, United States
- Floridian Clinical ResearchMiami Lakes, United States
- IMA Clinical ResearchMonroe, United States
- Catalina Research Institute, LLCMontclair, United States
- Delricht ResearchNew Orleans, United States
- IMA Clinical ResearchNew York, United States
- Velocity Clinical Research - NorfolkNorfolk, United States
- Healthcare Clinical Data, Inc.North Miami, United States
- Profound Research LLCOceanside, United States
- Velocity Clinical Research - OmahaOmaha, United States
- Optimal Research, LLCPeoria, United States
- DelRicht ResearchPrairieville, United States
- DelRicht ResearchProsper, United States
- Clinical Research Partners, LLCRichmond, United States
- Profound Research LLCRochester Hills, United States
- Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, United States
- Acclaim Clinical ResearchSan Diego, United States
- Velocity Clinical Research - Sioux CitySioux City, United States
- Spartanburg Medical ResearchSpartanburg, United States
- DelRicht ResearchSpringfield, United States
- Sundance Clinical Research, LLCSt Louis, United States
- Stephenville Medical & Surgical ClinicStephenville, United States
- Fiel Family and Sports Medicine/CCT ResearchTempe, United States
- Del Sol Research Management, LLCTucson, United States
- DelRicht ResearchTulsa, United States
- Velocity Clinical Research, ValparaisoValparaiso, United States
- Velocity Clinical Research, Salt Lake CityWest Jordan, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo.
The 4 groups in the trial
- CD388 Low DoseTreatment being tested
Participants are randomized to receive a low dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Treatment: CD388 Injection
- CD388 Medium DoseTreatment being tested
Participants are randomized to receive a medium dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Treatment: CD388 Injection
- CD388 High DoseTreatment being tested
Participants are randomized to receive a high dose of CD388 by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Treatment: CD388 Injection
- PlaceboPlacebo, for comparison
Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
- Record updated
- 18 June 2026